NCT04927858View on ClinicalTrials.gov

A Study Using Swedish Registries to Find Out How Many People With Type 2 Diabetes Had Cardiovascular Disease and Started Treatment With Empagliflozin Between 2015 and 2017

CompletedOBSERVATIONAL
Enrollment

460,558

Participants

Timeline

Start Date

April 2, 2018

Primary Completion Date

November 15, 2018

Study Completion Date

November 15, 2018

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

Empagliflozin

Empagliflozin

Trial Locations (1)

120 06

Boehringer Ingelheim AB, Stockholm

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT04927858 - A Study Using Swedish Registries to Find Out How Many People With Type 2 Diabetes Had Cardiovascular Disease and Started Treatment With Empagliflozin Between 2015 and 2017 | Biotech Hunter | Biotech Hunter